As vaccines will take around 12 months to develop, companies with antiviral treatments are now been pushed to the front line in the battle against coronavirus, and Gilead Sciences Inc.’s remdesivir is currently the biggest hope of a drug to treat infected patients.
The company had big news to talk about on 2 March at the Cowen Health Care conference, as it had announced earlier in the day the acquisition of oncology firm Forty Seven for $4.9bn
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?